疫苗研製再獲進展 生物疫苗概念股全線上漲
格隆匯6月17日丨A股國藥股份、華北製藥、北陸藥業漲停、邁克生物、達安基因、華蘭生物、魯抗醫藥、天壇生物等大漲;港股市場國藥控股漲超11%。中國生物官方微信發佈新冠滅活疫苗Ⅰ/Ⅱ期臨牀研究揭盲結果。臨牀試驗現場克服了疫情帶來的重重困難,全球首個獲得了新冠滅活疫苗2針接種後的安全性和有效性數據:疫苗接種後安全性好,無一例嚴重不良反應。不同程序、不同劑量接種後,疫苗組接種者均產生高滴度抗體,0,28天程序接種兩劑後中和抗體陽轉率達100%。據悉,疫苗的臨牀試驗分為三期,完成I-III期臨牀直至上市,預計最快需要到今年底或明年初。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.